Key Takeaways Starting dose: 2mg once weekly for the first 4 weeks to assess tolerance Titration schedule: Increase every 4 weeks: 2mg 4mg 8mg 12mg (max) Half-life: Approximately 6 days, reaching steady state in 4-5 weeks Injection frequency: Once weekly on the same day each week Microdosing option: Some users split doses for improved tolerability Investigational Drug: Retatrutide is NOT FDA-approved and is currently only available through clinical trials
The GLP-1 Support Patch was developed in response to consumer interest while maintaining clear scientific guardrails
Twelve (70.6%) patients were males, eight (50%) were white, and median age was 2.7 months
Cerebellum (2011) 10:438.10.1007/s12311-010-0223-4 108 AdamsJBAudhyaTMcDonough-MeansS
--- Mller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschp MH